Cargando…

COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab

Since the recent approval of vaccines against COVID-19, efficacy concerns emerged for MS patients treated with immunosuppressive drugs. We report our experience in four patients, under cladribine (two) or under ocrelizumab (two) treatment, all with low lymphocyte count, three of them vaccinated afte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Buttari, Fabio, Bruno, Antonio, Dolcetti, Ettore, Azzolini, Federica, Bellantonio, Paolo, Centonze, Diego, Fantozzi, Roberta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093161/ https://www.ncbi.nlm.nih.gov/pubmed/33990054 http://dx.doi.org/10.1016/j.msard.2021.102983

Ejemplares similares

Influence of Previous Disease-Modifying Drug Exposure on T-Lymphocyte Dynamic in Patients With Multiple Sclerosis Treated With Ocrelizumab
por: Landi, Doriana, et al.
Publicado: (2022)

Benign course of COVID-19 in a multiple sclerosis patient treated with Ocrelizumab
por: Suwanwongse, Kulachanya, et al.
Publicado: (2020)

Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice
por: De Angelis, Marcello, et al.
Publicado: (2020)

COVID-19 in persons with multiple sclerosis treated with ocrelizumab – A pharmacovigilance case series
por: Hughes, Richard, et al.
Publicado: (2020)

COVID-19 with no antibody response in a multiple sclerosis patient treated with cladribine: Implication for vaccination program?
por: Gelibter, Stefano, et al.
Publicado: (2021)

Favorable outcomes after COVID-19 infection in multiple sclerosis patients treated with cladribine tablets
por: Jack, Dominic, et al.
Publicado: (2020)

Theoretical and Therapeutic Implications of the Spasticity-Plus Syndrome Model in Multiple Sclerosis
por: Bruno, Antonio, et al.
Publicado: (2022)

Osteopontin Is Associated with Multiple Sclerosis Relapses
por: Stampanoni Bassi, Mario, et al.
Publicado: (2023)

Age at Disease Onset Associates With Oxidative Stress, Neuroinflammation, and Impaired Synaptic Plasticity in Relapsing-Remitting Multiple Sclerosis
por: Stampanoni Bassi, Mario, et al.
Publicado: (2021)

Neuroinflammation Is Associated with GFAP and sTREM2 Levels in Multiple Sclerosis
por: Azzolini, Federica, et al.
Publicado: (2022)

Multiple sclerosis patients treated with cladribine tablets: expert opinion on practical management after year 4
por: Centonze, Diego, et al.
Publicado: (2023)

CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis
por: Baker, David, et al.
Publicado: (2022)

Vaccination Opportunities in Multiple Sclerosis Patients Treated with Cladribine Tablets
por: Moiola, Lucia, et al.
Publicado: (2022)

Fatigue in Multiple Sclerosis Is Associated with Reduced Expression of Interleukin-10 and Worse Prospective Disease Activity
por: Gilio, Luana, et al.
Publicado: (2022)

Clinical outcomes of COVID-19 in patients with multiple sclerosis treated with ocrelizumab in the pre- and post-SARS-CoV-2 vaccination periods: Insights from Israel
por: Weberpals, Janick, et al.
Publicado: (2022)

COVID-19 in ocrelizumab-treated people with multiple sclerosis
por: Hughes, Richard, et al.
Publicado: (2021)

COVID-19 in Cladribine-treated patient with multiple sclerosis
por: Haham, Nitsan, et al.
Publicado: (2021)

Therapeutic recommendations and seasonal influenza vaccine for multiple sclerosis patients in treatment with ocrelizumab: an expert consensus
por: Filippi, Massimo, et al.
Publicado: (2021)

Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients
por: Allen-Philbey, Kimberley, et al.
Publicado: (2021)

Interleukin 6 SNP rs1818879 Regulates Radiological and Inflammatory Activity in Multiple Sclerosis
por: Bruno, Antonio, et al.
Publicado: (2022)

The Characterization of Regulatory T-Cell Profiles in Alzheimer’s Disease and Multiple Sclerosis
por: Ciccocioppo, Fausta, et al.
Publicado: (2019)

Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study
por: Petracca, Maria, et al.
Publicado: (2022)

Emerging Role of Extracellular Vesicles in the Pathophysiology of Multiple Sclerosis
por: Dolcetti, Ettore, et al.
Publicado: (2020)

Ocrelizumab: A Review in Multiple Sclerosis
por: Lamb, Yvette N.
Publicado: (2022)

The BDNF Val66Met Polymorphism (rs6265) Modulates Inflammation and Neurodegeneration in the Early Phases of Multiple Sclerosis
por: Dolcetti, Ettore, et al.
Publicado: (2022)

Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab
por: Iannetta, Marco, et al.
Publicado: (2020)

Inflammation-Associated Synaptic Alterations as Shared Threads in Depression and Multiple Sclerosis
por: Bruno, Antonio, et al.
Publicado: (2020)

A Model-Based Economic Evaluation of Cladribine Versus Alemtuzumab, Ocrelizumab and Natalizumab for the Treatment of Relapsing-Remitting Multiple Sclerosis with High Disease Activity in Chile
por: Espinoza, Manuel Antonio, et al.
Publicado: (2021)

Corrigendum: Inflammation-Associated Synaptic Alterations as Shared Threads in Depression and Multiple Sclerosis
por: Bruno, Antonio, et al.
Publicado: (2021)

Hypogammaglobulinemia, infections and COVID-19 in people with multiple sclerosis treated with ocrelizumab
por: Habek, Mario, et al.
Publicado: (2022)

COVID-19 in patients with multiple sclerosis treated with cladribine tablets: An update
por: Jack, Dominic, et al.
Publicado: (2021)

Exploiting the Multifaceted Effects of Cannabinoids on Mood to Boost Their Therapeutic Use Against Anxiety and Depression
por: Stampanoni Bassi, Mario, et al.
Publicado: (2018)

Varicella zoster virus and influenza vaccine antibody titres in patients from MAGNIFY-MS who were treated with cladribine tablets for highly active relapsing multiple sclerosis
por: Schmierer, Klaus, et al.
Publicado: (2022)

Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis
por: Cellerino, Maria, et al.
Publicado: (2021)

Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis
por: Savic, Radojka M., et al.
Publicado: (2017)

Multicenter Interventional Phase IV Study for the Assessment of the Effects on Patient's Satisfaction of Peg IFN Beta-1a (Pre-filled Pen) in Subjects With Relapsing–Remitting Multiple Sclerosis Unsatisfied With Other Injectable Subcutaneous Interferons (PLATINUM Study)
por: Centonze, Diego, et al.
Publicado: (2021)

Understanding the impacts of COVID-19 pandemic in people with multiple sclerosis treated with ocrelizumab
por: Pedotti, Rosetta, et al.
Publicado: (2021)

COVID-19 in cladribine-treated relapsing-remitting multiple sclerosis patients: a monocentric experience
por: Preziosa, Paolo, et al.
Publicado: (2020)

Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis
por: Alvarez‐Gonzalez, Cesar, et al.
Publicado: (2017)

Outcomes of COVID-19 in people with multiple sclerosis treated with cladribine tablets: an update
por: Jack, Dominic, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_u9dkn72ddqa2v0v6jd8pnbb3qm